Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) in Cardiac Amyloidosis: A Systematic Review: Study protocol

This systemic review highlights the potential of SGLT2i to improve functional and cardiovascular outcomes in cardiac amyloidosis while maintaining an acceptable safety profile. Despite these promising results, further randomized controlled trials are necessary to confirm the findings and define the role of SGLT2i in managing cardiac amyloidosis. Until then, clinicians should cautiously integrate SGLT2i into treatment strategies based on individual patient characteristics and clinical context.